Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82,378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles.
Sharma HS, Feng L, Chen L, Huang H, Ryan Tian Z, Nozari A, Muresanu DF, Lafuente JV, Castellani RJ, Wiklund L, Sharma A. Sharma HS, et al. Among authors: chen l. Neurochem Res. 2023 Jun;48(6):1864-1888. doi: 10.1007/s11064-023-03861-8. Epub 2023 Jan 31. Neurochem Res. 2023. PMID: 36719560 Free PMC article.
Nanodelivery of Histamine H3/H4 Receptor Modulators BF-2649 and Clobenpropit with Antibodies to Amyloid Beta Peptide in Combination with Alpha Synuclein Reduces Brain Pathology in Parkinson's Disease.
Buzoianu AD, Sharma A, Muresanu DF, Feng L, Huang H, Chen L, Tian ZR, Nozari A, Lafuente JV, Wiklund L, Sharma HS. Buzoianu AD, et al. Among authors: chen l. Adv Neurobiol. 2023;32:55-96. doi: 10.1007/978-3-031-32997-5_2. Adv Neurobiol. 2023. PMID: 37480459 Review.
Nanodelivery of histamine H3 receptor inverse agonist BF-2649 with H3 receptor antagonist and H4 receptor agonist clobenpropit induced neuroprotection is potentiated by antioxidant compound H-290/51 in spinal cord injury.
Buzoianu AD, Sharma A, Muresanu DF, Feng L, Huang H, Chen L, Tian ZR, Nozari A, Lafuente JV, Sjöqvist PO, Wiklund L, Sharma HS. Buzoianu AD, et al. Among authors: chen l. Int Rev Neurobiol. 2023;172:37-77. doi: 10.1016/bs.irn.2023.06.003. Epub 2023 Sep 26. Int Rev Neurobiol. 2023. PMID: 37833018
The 2020 Yearbook of Neurorestoratology.
Huang H, Chen L, Chopp M, Young W, Robert Bach J, He X, Sarnowaska A, Xue M, Chunhua Zhao R, Shetty A, Siniscalco D, Guo X, Khoshnevisan A, Hawamdeh Z. Huang H, et al. Among authors: chen l. J Neurorestoratology. 2021 Mar 5;9(1):1-12. doi: 10.26599/JNR.2021.9040002. Epub 2022 May 10. J Neurorestoratology. 2021. PMID: 37387779 Free PMC article. Review.
Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities: The FOCUS Randomized Clinical Trial.
Ji H, Zhao X, Chen X, Fang H, Gao H, Wei G, Zhang M, Kuang H, Yang B, Cai X, Su Y, Piao C, Zhao S, Li L, Sun W, Xu T, Xu Q, Fan Y, Ye J, Yao C, Shang M, Song G, Chen L, Zheng Q, Xiao X, Yan L, Lian F, Tong X, Jia Z; FOCUS Trial Committees and Investigators. Ji H, et al. Among authors: chen l. JAMA Intern Med. 2024 Jun 3. doi: 10.1001/jamainternmed.2024.1190. Online ahead of print. JAMA Intern Med. 2024. PMID: 38829648
82,378 results
You have reached the last available page of results. Please see the User Guide for more information.